-
Investing in UK universities: spin research into profitsUK universities are a vital economic asset, but they are also Britain's 'equivalent of Gulf oil.' There are opportunities here for investors
-
Healthcare stocks look cheap, but tread carefullyShares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?
-
UK equities: where to find a great British bargainUK equities are staging a comeback, but there’s still plenty of value out there, says Rupert Hargreaves
-
Cash in on the biotech boom with three promising European picksOpinion Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d put their money
Opinion -
Precision-engineered profits: How to invest in genomicsDevelopments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals. Smart investors should buy in now, says Matthew Partridge
-
Anne Wojcicki: the daring 23andMe CEO who reached too farProfile Anne Wojcicki dreamed of a revolution in personal genomics and medicine and set up 23andMe in 2006. Its collapse into bankruptcy provides a cautionary tale
Profile -
Cash in on the biotech sector with specialist BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
Opinion -
How to invest in weight-loss drugsThe new generation of weight-loss drugs are a boon for the overweight, but they also promise to change our relationship with food and revolutionise the economy
-
Vertex Pharmaceuticals is a rare opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
